HC Wainwright Comments on Lineage Cell Therapeutics FY2026 Earnings

Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX – Free Report) – Equities researchers at HC Wainwright upped their FY2026 EPS estimates for Lineage Cell Therapeutics in a research note issued to investors on Friday, November 13th. HC Wainwright analyst J. Pantginis now forecasts that the company will earn ($0.01) per share for the year, up from their prior estimate of ($0.08). The consensus estimate for Lineage Cell Therapeutics’ current full-year earnings is ($0.07) per share. HC Wainwright also issued estimates for Lineage Cell Therapeutics’ Q4 2026 earnings at ($0.02) EPS, FY2027 earnings at ($0.07) EPS and FY2028 earnings at ($0.07) EPS.

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX – Get Free Report) last announced its quarterly earnings data on Thursday, November 12th. The company reported ($0.03) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.03). The business had revenue of $1.43 million during the quarter, compared to analyst estimates of $2.32 million. Lineage Cell Therapeutics had a return on equity of 3.37% and a net margin of 16.18%.

Separately, Raymond James Financial reaffirmed a “market perform” rating on shares of Lineage Cell Therapeutics in a research report on Friday. Four investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $6.25.

Check Out Our Latest Research Report on Lineage Cell Therapeutics

Lineage Cell Therapeutics Stock Performance

Shares of NYSEAMERICAN LCTX opened at $0.80 on Tuesday. The business’s 50-day moving average price is $0.99 and its two-hundred day moving average price is $1.29. Lineage Cell Therapeutics has a one year low of $0.77 and a one year high of $1.99.

Institutional Trading of Lineage Cell Therapeutics

A number of institutional investors have recently added to or reduced their stakes in LCTX. Goldman Sachs Group Inc. increased its stake in shares of Lineage Cell Therapeutics by 24.2% during the 3rd quarter. Goldman Sachs Group Inc. now owns 537,965 shares of the company’s stock worth $514,000 after purchasing an additional 104,699 shares during the last quarter. Empowered Funds LLC bought a new position in shares of Lineage Cell Therapeutics during the 3rd quarter valued at $208,000. Fifth Third Bancorp raised its holdings in shares of Lineage Cell Therapeutics by 6.5% during the 3rd quarter. Fifth Third Bancorp now owns 4,900,000 shares of the company’s stock valued at $4,683,000 after purchasing an additional 300,000 shares in the last quarter. StoneX Group Inc. raised its holdings in shares of Lineage Cell Therapeutics by 74.9% during the 3rd quarter. StoneX Group Inc. now owns 29,747 shares of the company’s stock valued at $30,000 after purchasing an additional 12,739 shares in the last quarter. Finally, Defender Capital LLC. lifted its stake in shares of Lineage Cell Therapeutics by 0.8% in the 3rd quarter. Defender Capital LLC. now owns 6,648,899 shares of the company’s stock valued at $6,354,000 after purchasing an additional 50,000 shares during the last quarter. 62.47% of the stock is currently owned by institutional investors and hedge funds.

Lineage Cell Therapeutics Company Profile

(Get Free Report)

Lineage Cell Therapeutics is a biotechnology company developing cell-based therapies for serious medical conditions. The company uses its cell therapy platform to create and manufacture specialized human cells intended to replace or support damaged cells and tissues. Its programs include OpRegen, a retinal pigment epithelial cell therapy being developed for retinal diseases; OPC1, an oligodendrocyte progenitor cell therapy for spinal cord injury; ANP1, an auditory neuron progenitor cell program for hearing loss; and VAC2, a cell-based cancer immunotherapy.

See Also

Earnings History and Estimates for Lineage Cell Therapeutics (NYSEAMERICAN:LCTX)

Receive News & Ratings for Lineage Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lineage Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.